A Study of YL242 in Subjects With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMediLink Therapeutics (Suzhou) Co., Ltd.
About this trial
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Eligibility criteria
Qualifiers
Aged ≥18 years.
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
Adequate organ and bone marrow function
Disqualifiers
Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases
Clinically significant concomitant pulmonary disease
A history of leptomeningeal carcinomatosis or carcinomatous meningitis
Trial design
Treatments tested in this trial
- YL242
- YL242; Pembrolizumab
- YL242; 5-FU; LV
- YL242; Pembrolizumab; 5-FU
Treatment groups
424 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov